Lack of effect from genetic deletion of Hdac6 in a humanized mouse model of CMT2D
Journal of the Peripheral Nervous System · 2024
DOI: 10.1111/jns.12623 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Peripheral Nervous System, 2024. Verfasst von Abigail L D Tadenev und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Jackson Laboratory, Bar Harbor, Maine, USA. Hauptthemen laut MEDLINE: Charcot-Marie-Tooth Disease, Histone Deacetylase 6, Disease Models, Animal. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, Charcot-Marie-Tooth Association, NINDS NIH HHS.
Abstract (Originalsprache)
Background
Inhibition of HDAC6 has been proposed as a broadly applicable therapeutic strategy for Charcot–Marie–Tooth disease (CMT). Inhibition of HDAC6 increases the acetylation of proteins important in axonal trafficking, such as α‐tubulin and Miro, and has been shown to be efficacious in several preclinical studies using mouse models of CMT.
Aims
Here, we sought to expand on previous preclinical studies by testing the effect of genetic deletion of Hdac6 on mice carrying a humanized knockin allele of Gars1 , a model of CMT‐type 2D.
Methods
Gars1 ΔETAQ mice were bred to an Hdac6 knockout strain, and the resulting offspring were evaluated for clinically relevant outcomes.
Results
The genetic deletion of Hdac6 increased α‐tubulin acetylation in the sciatic nerves of both wild‐type and Gars1 ΔETAQ mice. However, when tested at 5 weeks of age, the Gars1 ΔETAQ mice lacking Hdac6 showed no changes in body weight, muscle atrophy, grip strength or endurance, sciatic motor nerve conduction velocity, compound muscle action potential amplitude, or peripheral nerve histopathology compared to Gars1 ΔETAQ mice with intact Hdac6 .
Interpretation
Our results differ from those of two previous studies that demonstrated the benefit of the HDAC6 inhibitor tubastatin A in mouse models of CMT2D. While we cannot fully explain the different outcomes, our results offer a counterexample to the benefit of inhibiting HDAC6 in CMT2D, suggesting additional research is necessary.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Jackson Laboratory, Bar Harbor, Maine, USA.
ORCID-Profile: Abigail L D Tadenev, Robert W Burgess
Förderung
- NIH HHS
- Charcot-Marie-Tooth Association
- NINDS NIH HHS
- NCI NIH HHS
- National Cancer Institute
- National Institute of Neurological Disorders and Stroke
- National Institutes of Health
Zitieren
APA
Tadenev, A. L. D., Hatton, C. L., & Burgess, R. W. (2024). Lack of effect from genetic deletion of Hdac6 in a humanized mouse model of CMT2D. Journal of the Peripheral Nervous System. https://doi.org/10.1111/jns.12623
Vancouver
Tadenev ALD, Hatton CL, Burgess RW. Lack of effect from genetic deletion of Hdac6 in a humanized mouse model of CMT2D. Journal of the Peripheral Nervous System. 2024. doi:10.1111/jns.12623
BibTeX
@article{Tadenev2024,
author = {Tadenev, Abigail L D and Hatton, Courtney L and Burgess, Robert W},
title = {Lack of effect from genetic deletion of Hdac6 in a humanized mouse model of CMT2D},
journal = {Journal of the Peripheral Nervous System},
year = {2024},
doi = {10.1111/jns.12623}
}
EUVIMED